Literature DB >> 15115953

Cholestasis: human disease and experimental animal models.

Emilio Alberto Rodríguez-Garay1.   

Abstract

Cholestasis may result from a failure in bile secretion in hepatocytes or ductular cells, or from a blockade to the free bile flow. Human cholestasis may be induced by many drugs, being antibiotics the more common. Other types of cholestasis seen in humans are a group of familial cholestatic disorders, obstructive cholestasis, primary biliary cirrhosis, extrahepatic biliary atresia, primary sclerosing cholangitis, cholestasis of pregnancy, oral contraceptive-induced cholestasis, and sepsis-induced cholestasis. Experimental animal models allow the understanding of pathophysiological mechanisms involved and their clinical correlates. The most common experimental models of intrahepatic cholestasis are estrogen-induced, endotoxin-induced and drug-induced cholestasis. A well known model of extrahepatic biliary obstruction is common bile duct ligation. Drug-induced cholestasis were described using different drugs. On this regard, alpha naphthylisothiocyanate treatment has been extensively used, permitting to describe not only cholestatic alterations but also compensatory mechanisms. Congenital defficiency of transport proteins also were studied in natural rat models of cholestasis. The experimental animal models allow to define down-regulated alterations of hepatocyte transport proteins, and up-regulated ones acting as compensatory mechanisms. In conclusion, animal model and transport protein studies are necessary for the progressive understanding of congenital and acquired human cholestasis, and regulatory mechanisms that operate on liver cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15115953

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  35 in total

1.  Effects of statins on cholestasis: good, bad or indifferent?

Authors:  Rahul Kuver
Journal:  J Gastroenterol Hepatol       Date:  2011-10       Impact factor: 4.029

2.  Purposeful Repurposing: Unexpected but Not Necessarily Unwelcome Effects of Dexmedetomidine.

Authors:  Melanie J Scott
Journal:  Crit Care Med       Date:  2015-09       Impact factor: 7.598

3.  Bioenergetics of mitochondria of the liver with biliary atresia during prolonged starvation.

Authors:  M V Savina; L V Emel'yanova; S M Korotkov; I V Brailovskaya; A D Nadeev
Journal:  Dokl Biochem Biophys       Date:  2009 Mar-Apr       Impact factor: 0.788

4.  Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity.

Authors:  J J Sutherland; Y W Webster; J A Willy; G H Searfoss; K M Goldstein; A R Irizarry; D G Hall; J L Stevens
Journal:  Pharmacogenomics J       Date:  2017-04-25       Impact factor: 3.550

5.  Hepatic damage in biliary-obstructed rats is ameliorated by leflunomide treatment.

Authors:  Abdurrahman Karaman; Mustafa Iraz; Hale Kirimlioglu; Nese Karadag; Erkan Tas; Ersin Fadillioglu
Journal:  Pediatr Surg Int       Date:  2006-08-05       Impact factor: 1.827

6.  Tissue factor-dependent coagulation contributes to alpha-naphthylisothiocyanate-induced cholestatic liver injury in mice.

Authors:  James P Luyendyk; Glenn H Cantor; Daniel Kirchhofer; Nigel Mackman; Bryan L Copple; Ruipeng Wang
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-01-29       Impact factor: 4.052

7.  Pharmacokinetic Characteristics of Baicalin in Rats with 17α-ethynyl-estradiol-induced Intrahepatic Cholestasis.

Authors:  Cheng-Liang Zhang; Yan-Jiao Xu; Dong Xiang; Jin-Yu Yang; Kai Lei; Dong Liu
Journal:  Curr Med Sci       Date:  2018-03-15

8.  The hepatitis B virus X protein modulates hepatocyte proliferation pathways to stimulate viral replication.

Authors:  Tricia L Gearhart; Michael J Bouchard
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

9.  Hepatitis B virus X protein modulates apoptosis in primary rat hepatocytes by regulating both NF-kappaB and the mitochondrial permeability transition pore.

Authors:  Amy J Clippinger; Tricia L Gearhart; Michael J Bouchard
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

10.  Dominant-negative NFKBIA mutation promotes IL-1β production causing hepatic disease with severe immunodeficiency.

Authors:  Enrica Ek Tan; Richard A Hopkins; Chrissie K Lim; Saumya S Jamuar; Christina Ong; Koh C Thoon; Mark Ja Koh; Eun Mong Shin; Derrick Wq Lian; Madhushanee Weerasooriya; Christopher Zw Lee; Andreas Alvin Pumomo Soetedjo; Chang Siang Lim; Veonice B Au; Edmond Chua; Hui Yin Lee; Leigh Ann Jones; Sharmy S James; Nivashini Kaliaperumal; Jeffery Kwok; Ee Shien Tan; Biju Thomas; Lynn Xue Wu; Lena Ho; Anna Marie Fairhurst; Florent Ginhoux; Adrian Kk Teo; Yong Liang Zhang; Kok Huar Ong; Weimiao Yu; Byrappa Venkatesh; Vinay Tergaonkar; Bruno Reversade; Keh Chuang Chin; Ah Moy Tan; Woei Kang Liew; John E Connolly
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.